AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00702923
Drug: Bicalutamide, CP-675,206 (tremelimumab)
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose level 1:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 6 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)
Trial: NCT00702923
Drug: Bicalutamide, CP-675,206 (Tremelimumab)
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose level 2:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 10 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)
Trial: NCT00702923
Drug: Bicalutamide, CP-675,206 (Tremelimumab)
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose level 3:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 15 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)
Trial: NCT00702923
Drug: Bicalutamide, CP-675,206
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Final Dose Level:~Bicalutamide 150 mg p.o. q.d. day 1-28, day 85-112~At month 9, if evidence of PSA progression:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 (MTD dose) I.V. over 1 hour, day 29
Trial: NCT00115609
Drug: efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800mg for patients treated by rifampicine 600mg for other patients
Trial: NCT00115609
Drug: tenofovir DF
RxNorm normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300mg once a day
Trial: NCT00115609
Drug: emtricitabine
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: one pill of 200mg once a day
Trial: NCT04155749
Drug: anitocabtagene-autoleucel
RxNorm normalized name: Brexucabtagene autoleucel
DrugBank: Anitocabtagene autoleucel (DB18881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric Antigen Receptor T cells
Trial: NCT00605423
Drug: Fluocinolone Acetonide/Medidur
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2 ug/day implant
Trial: NCT00605423
Drug: Fluocinolone Acetonide/Medidur
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 ug/day implant
Trial: NCT00633659
Drug: Hemospan (MP4OX)
RxNorm normalized name: Aerospan
DrugBank: MP4 (DB05313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL of Hemospan (MP4OX)
Trial: NCT00633659
Drug: Voluven (HES 130/0.4)
RxNorm normalized name: hydroxyethyl starch 130-0.4 Injection [Voluven]
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL of Voluven (HES 130/0.4) solution
Trial: NCT04106700
Drug: Apixaban 2.5 MG
RxNorm normalized name: apixaban 2.5 MG
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban will be started simultaneously with anti myeloma treatment on day 1 of cycle 1 of VTD, and continues for 4 to 6 months depending on the number of induction cycles administered to the patient
Trial: NCT00586261
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg daily for 6 months
Trial: NCT00586261
Drug: Nitroglycerin
RxNorm normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg sublingual nitroglycerin tablet was given to all patients without a contraindication to check the brachial reactivity.
Trial: NCT03762759
Drug: Fluciclovine F18
RxNorm normalized name: FLUCICLOVINE F18 (9-221 MCI/ML) INJ
DrugBank: Fluciclovine (18F) (DB13146)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03339661
Drug: Group 2A_Proph treatment and γδ T cell expansion
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum. The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A.
Trial: NCT03339661
Drug: Group 2B_Proph treatment and no γδ T cell expansion
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum. Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
Trial: NCT01663233
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine will use tablets available at a strength of 5 mg. Patients will be instructed to take the prescribed medication once a day.
Trial: NCT02321098
Drug: Loceryl NL + Cosmetic varnish
RxNorm normalized name: Botox Cosmetic
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Loceryl NL + Cosmetic varnish once/week for 12 weeks
Trial: NCT02321098
Drug: Loceryl NL 15 months
RxNorm normalized name: Loceryl
DrugBank: Amorolfine (DB09056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loceryl once/week for additional 15 months
Trial: NCT00007605
Drug: Amiodarone
RxNorm normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients assigned will receive 400 mg bid for 14 days, 400 mg QAM and 200 mg QHS for 14 days, 300 mg qd for 48 weeks, then 200 mg qd.
Trial: NCT00007605
Drug: Sotalol
RxNorm normalized name: Sotalol
DrugBank: Sotalol (DB00489)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients assigned will receive 80 mg bid for 7 days and 160 mg bid thereafter.
Trial: NCT03610061
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing.
Trial: NCT02222207
Drug: Regorafenib, ophthalmic oily suspension (BAY73-4506)
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects receive Regorafenib as eye drops
Trial: NCT02222207
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects receive Ranibizumab as intravitreal injection
Trial: NCT03976037
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women randomized to either vaginal or buccal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of vaginal or buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~vaginal or Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated.
Trial: NCT00848861
Drug: propofol (sedation for outpatient colonoscopy)
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00848861
Drug: midazolam plus meperidine (sedation for outpatient colonoscopy)
DrugBank: Meperidine (DB00454)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01114503
Drug: Otelixizumab - low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Otelixizumab (DB05496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 day dose rising intravenous infusions of a low dose of otelixizumab
Trial: NCT01114503
Drug: Otelixizumab - medium low dose
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Otelixizumab (DB05496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 day dose rising intravenous infusions of a medium low dose of otelixizumab
Trial: NCT01114503
Drug: Otelixizumab - medium high dose
RxNorm normalized name: high-density polyethylene
DrugBank: Otelixizumab (DB05496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 day dose rising intravenous infusions of a medium high dose of otelixizumab
Trial: NCT01114503
Drug: Otelixizumab - high dose
RxNorm normalized name: high-density polyethylene
DrugBank: Otelixizumab (DB05496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 day dose rising intravenous infusions of a high dose of otelixizumab
Trial: NCT01114503
Drug: Otelixizumab
RxNorm normalized name: Otelixizumab
DrugBank: Otelixizumab (DB05496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 day dose rising intravenous infusions of otelixizumab administered at a dose decided upon results from Part A.
Trial: NCT01114503
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly intravenous infusions of methylprednisolone administered as 500 mg per week for 6 weeks and then 250 mg per week for 6 weeks
Trial: NCT00622648
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg once daily for 6 to 14 days (10 ± 4 days)
Trial: NCT03108313
Drug: aloe vera toothpaste
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: herbal toothpaste used to decrease salivary streptococcus bacterial count
Trial: NCT03108313
Drug: fluoride toothpaste
RxNorm normalized name: sodium fluoride Toothpaste
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemical toothpaste used to decrease salivary streptococcus bacterial count
Trial: NCT02187471
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin capsule for oral use; 75 mg capsule for one week, then 150 mg capsule
Trial: NCT00004231
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004231
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004231
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004231
Drug: teniposide
RxNorm normalized name: Teniposide
DrugBank: Teniposide (DB00444)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004231
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00631371
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 10 mg/kg intravenous (IV) q8wks
Trial: NCT00631371
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus 25 mg IV weekly
Trial: NCT00631371
Drug: Interferon-Alfa 9MU
RxNorm normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-Alfa 9MU SC TIW
Trial: NCT03285594
Drug: Sotagliflozin
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Trial: NCT03285594
Drug: Insulin glargine (HOE901)
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Trial: NCT01815307
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2, day 1 every 2 weeks
Trial: NCT01815307
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 80mg/m2/day, day 1-28, every 6 weeks
Trial: NCT00665457
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04195321
Drug: phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: infusion will be started after induction of spinal anesthesia
Trial: NCT02325219
Drug: CNTO 1959 50 mg
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
DrugBank: Carlumab (DB12718)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive subcutaneous injection of CNTO 1959 50 mg.
Trial: NCT00439946
Drug: treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: rapid switch from intravenous epoprostenol on the CADD ambulatory pump to intravenous Remodulin on the Crono Five ambulatory pump
Trial: NCT03426085
Drug: Liraglutide 6 mg Solution for Injection
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01616927
Drug: Lanreotide
RxNorm normalized name: Lanreotide
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanreotide will be administered once every 4 weeks as a subcutaneous injection
Trial: NCT00935168
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maximum dose of 50ml/kg/day of saline for intravascular volume fluid resuscitation
Trial: NCT05069246
Drug: Chlorhexidine mouthwash
RxNorm normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10ml of chlorohexidine mouthwash used for 3mins and spit out, used twice a day; morning and evening.
Trial: NCT00834431
Drug: Famciclovir 500 mg Tablets
RxNorm normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 x 500 mg, single-dose fasting
Trial: NCT01684774
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00878020
Drug: BMS-830216
RxNorm normalized name: BMS-830216
DrugBank: BMS-830216 (DB14787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, Single Dose, 1 day
Trial: NCT00878020
Drug: BMS-830216
RxNorm normalized name: BMS-830216
DrugBank: BMS-830216 (DB14787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, Single Dose on Day 1, Period 1 and Day 1, Period 2, 2 days
Trial: NCT02177422
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: telmisartan 80 mg once daily
Trial: NCT02177422
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12.5 mg or 25 mg Hydrochlorothiazide in addition to telmisartan in case that the goal response (mean sitting diastolic blood pressure \< 90 mmHg) is not met after at least 4 weeks of treatment with telmisartan
Trial: NCT01263171
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00286273
Drug: trisodium citrate
RxNorm normalized name: TRISODIUM CITRATE
DrugBank: Sodium phosphate tribasic dodecahydrate (DB14622)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for regional anticoagulation of the extracorporeal CVVH circuit
Trial: NCT00286273
Drug: nadroparin
RxNorm normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for anticoagulation of the extracorporeal CVVH circuit
Trial: NCT02750540
Drug: Tenofovir enema
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04192487
Drug: Crofelemer delayed-release tablets 125mg
RxNorm normalized name: crofelemer Delayed Release Oral Tablet
DrugBank: Crofelemer (DB04941)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 crofelemer delayed-release tablet twice daily at least 8 hours apart for 30 days with or without meals.
Trial: NCT03165097
Drug: ACT-709478
RxNorm normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hard gelatine capsules for oral administration
Trial: NCT03165097
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam oral solution (2 mg/mL) applied with a syringe
Trial: NCT03165097
Drug: ACT-709478 combined with midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hard gelatine capsules for oral administration (ACT-709478) to be taken first followed by Midazolam oral solution (2 mg/mL) applied with a syringe
Trial: NCT00925015
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan was administered with an intravenous infusion of 150 mg/m\^2, once every other week for 42 days
Trial: NCT03588923
Drug: SH229
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tablet, oral, 400 mg once daily for 3 days
Trial: NCT03588923
Drug: SH229
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tablet, oral, 600 mg once daily for 3 days
Trial: NCT03588923
Drug: SH229
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tablet, oral, 800 mg once daily for 3 days
Trial: NCT01255527
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib i.v. 0.7, 1.0 and 1.3 mg/m²/day
Trial: NCT03637764
Drug: Isatuximab SAR650984
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Trial: NCT03637764
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Trial: NCT00209781
Drug: Sulfadoxine-Pyrimethamine (Fansidar)
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03335527
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.1-0.2 ug/kg/h (0.025-0.05 ml/kg/h) from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.
Trial: NCT00773812
Drug: mecamylamine
RxNorm normalized name: Mecamylamine
DrugBank: Mecamylamine (DB00657)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage is titrated at 6 weeks of .5mg, 2 weeks of 2.5 mg, and 6 weeks of 5.0 mg. One pill is taken once daily.
Trial: NCT05220527
Drug: Triamcinolone plus hyruan
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: triamcinolone plus hyruan injections, one time per week, for 3 weeks
Trial: NCT05220527
Drug: normal saline plus hyruan
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline plus hyruan injections, one time per week, for 3 weeks
Trial: NCT02127463
Drug: MC-1101
RxNorm normalized name: MC-3
DrugBank: MC-1 (DB05315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically, two times a day, morning and bedtime
Trial: NCT02127463
Drug: MC-1101 Vehicle
RxNorm normalized name: MC-3
DrugBank: MC-1 (DB05315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically, two times a day; morning and bedtime
Trial: NCT02158234
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 15 mg/m\^2 prior to each fraction
Trial: NCT00003345
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003345
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04400890
Drug: Resveratrol
RxNorm normalized name: Resveratrol
DrugBank: Resveratrol (DB02709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol vs placebo given for 15 days.
Trial: NCT03335527
Drug: Placebo (normal saline)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025-0.05 ml/kg/h from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.
Trial: NCT00221299
Drug: Risedronate
RxNorm normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 35mg tab of risedronate/placebo taken once a week for one year.